DESLORATADINE ALLERGY CONTROL TABLET
Land: Canada
Sprog: engelsk
Kilde: Health Canada
Produktets egenskaber
(SPC)
12-09-2023
Nogle dokumenter til dette produkt er ikke tilgængelige i øjeblikket, du kan sende en anmodning til vores kundeservice, og vi vil underrette dig, så snart vi er i stand til at få dem.
Send anmodning.
Send anmodning.
Aktiv bestanddel:
DESLORATADINE
Tilgængelig fra:
PHARMASCIENCE INC
ATC-kode:
R06AX27
INN (International Name):
DESLORATADINE
Dosering:
5MG
Lægemiddelform:
TABLET
Sammensætning:
DESLORATADINE 5MG
Indgivelsesvej:
ORAL
Enheder i pakken:
10/20/30/50
Recept type:
OTC
Terapeutisk område:
SECOND GENERATION ANTIHISTAMINES
Produkt oversigt:
Active ingredient group (AIG) number: 0143961001; AHFS:
Autorisation status:
APPROVED
Autorisation dato:
2009-11-06
Produktets egenskaber
_DESLORATADINE ALLERGY _CONTROL page 1 of 37
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
DESLORATADINE ALLERGY CONTROL
Desloratadine
Tablet, 5mg, Oral
House Standard
Histamine H1-Receptor Antagonist
PHARMASCIENCE INC.
6111 Royalmount Avenue, Suite 100
Montréal, Canada
H4P 2T4
Date of initial Authorization:
SEP 22, 2011
Date of Revision:
SEP 12, 2023
Submission Control Number: 272961
_DESLORATADINE ALLERGY _CONTROL page 2 of 37
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................................................
4
1
INDICATIONS
....................................................................................................................................
4
1.1
PEDIATRICS
....................................................................................................................................
4
1.2
GERIATRICS
....................................................................................................................................
4
2
CONTRAINDICATIONS
.......................................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
..................................................................................
4
4
DOSAGE AND ADMINISTRATION
.......................................................................................................
4
4.1
DOSING CONSIDERATIONS
................................................................................................................
4
4.2
RECOMMENDED DOSE AND DOSAGE ADJUSTMENT
.............................................................................
5
4.3
ADMINISTRATION
............................................................................................................................
5
4.4
MISSED DOSE
................................................................................................................................
5
5
OVERDOSAGE
......................................
Læs hele dokumentet
